Nano Dimension provides update on proposed Infinite Epigenetics acquisition, values company at net cash plus 20% premium

Nano Dimension Ltd.

Infinite Epigenetics is a commercial diagnostics platform with CLIA-certified lab, >120K samples, and >7,500 healthcare providers.
Deal values Nano at net cash plus 20% premium; capital to accelerate commercialization and biological AI platform development.
Nano responds to Murchinson Ltd. criticisms, highlighting board's rigorous review and alignment with shareholder interests.
Infinite's AI platform uses proprietary DNA methylation data (one of world's largest private datasets), targeting >$90B chronic disease market.
No transaction-driven compensation for Nano board; shareholders will vote on definitive agreement once finalized.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.